<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475020</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0726</org_study_id>
    <secondary_id>NCI-2012-01477</secondary_id>
    <nct_id>NCT00475020</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if using a combination of fludarabine,
      busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or
      myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant.
      The safety of these drugs will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan is a chemotherapy drug that kills cancer cells by binding to DNA, and is commonly
      used in stem cell transplants. Fludarabine is a drug that has anti-leukemia and
      immunosuppressive effects. ATG helps to reduce the risk of transplant rejection and to
      prevent graft versus host disease.

      You will receive fludarabine by vein over 1 hour on Days -5 to -2. You will receive busulfan
      by vein over 3 hours on Day -5 to -2 immediately after completing fludarabine. If you have an
      unrelated or a mismatched donor, you will receive ATG by vein over 6 hours on Days -3 to -1
      to prevent graft versus host disease and to help engraftment.

      You will first receive a low-level &quot;test&quot; dose of busulfan, and blood samples (about 1
      teaspoon each time) will be drawn for pharmacokinetic (PK) tests. This may be done as an
      outpatient prior to inpatient admission. PK tests measure the level of the study drug in the
      blood over different time points. This information will be used to decide the next dose
      needed to reach the target blood level that matches your body size.

      About 11 total samples of blood will be drawn for PK testing after the test dose and before
      the first high-dose busulfan treatment. A heparin lock will be placed in your vein to lower
      the number of needle sticks needed for these draws. If it is not possible for these blood
      level tests to be performed for technical or scheduling reasons or for any other reason, you
      will receive the standard fixed busulfan dose without the &quot;test dose.&quot;

      You will receive the donor bone marrow or blood stem cells by vein over about 1 hour on Day
      0.

      Two (2) days before the stem cell infusion on Day -2, tacrolimus will be started as a
      non-stop infusion by vein and will be changed to oral tablets before you leave the hospital.
      You will continue to take tacrolimus by mouth, for at least 4 months.

      Four (4) doses of Methotrexate will be give as a short infusion Day 1, Day 3, Day 6 and Day
      11 after stem cell infusion. Both these are given to decrease the risk of getting
      graft-vs-host disease (GvHD). Further immunosuppressive therapy with methylprednisolone (a
      steroid) or other drugs may also be used to treat GvHD if it occurs.

      You will have 3 teaspoonfuls of blood drawn for routine tests every day while you are in the
      hospital and at least 2 times a week for the first 100 days after transplant. You may need
      frequent blood transfusions and may have to be admitted to the hospital to receive
      antibiotics if you get a fever. Three (3) teaspoonful of blood and a bone marrow aspirate and
      biopsy will be taken 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months after
      the transplant to check the response to the treatment. After the first 2 years, your disease
      status will be followed by a yearly phone call or letter from you or your regular doctor to
      the study doctor.

      Tests and/or procedures may be performed before the scheduled time, if your doctor thinks it
      is needed.

      You will be taken off the study if your disease gets worse or if further treatment is not in
      your best interest.

      This is an investigational study. All the drugs to be used in this study are FDA approved and
      commercially available. About 110 patients will take part in this study. All will be enrolled
      at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2006</start_date>
  <completion_date type="Actual">October 4, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Non-relapse Mortality at 100 Days Post-transplant</measure>
    <time_frame>Non-relapse mortality at 100 days post-transplant</time_frame>
    <description>To evaluate the safety of Fludarabine/Busulfan as conditioned regimen for allogeneic stem cell transplantation in patients with myelofibrosis/myelodysplastic syndrome at 100 days post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of This Therapy 3 Years Post-transplant</measure>
    <time_frame>Up to 3 years post-transplant</time_frame>
    <description>Efficacy Assessed as Number of Participants with Overall Survival, Leukemia Progression, Primary Graft Failure and Complete Hematological Response. Primary graft failure is defined as failure to achieve an ANC &gt;/= 0.5 x 10 (9)/L for 3 consecutive days and evidence of donor chimerism by Day +28. Complete hematological response is defined by hemoglobin &gt;/= 120 g/L; or achievement of transfusion independence, with stable Hb &gt; 110 g/L, for RBC transfusion-dependent participants; Spleen not palpable; platelet count 150 x 10 (9)/L; White blood cell 4 x 10 (9)/L to 10 x 10(9)/L.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Busulfan + Thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 40 mg/m^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days</description>
    <arm_group_label>Fludarabine + Busulfan + Thymoglobulin</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>40 mg/m^2 by vein daily over 1 hour x 4 days</description>
    <arm_group_label>Fludarabine + Busulfan + Thymoglobulin</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin (ATG)</intervention_name>
    <description>2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor</description>
    <arm_group_label>Fludarabine + Busulfan + Thymoglobulin</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Thymoglobulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Idiopathic Myelofibrosis or Myelofibrosis secondary to Polycythemia Vera
             or Essential Thrombocythemia or Myelodysplastic syndrome with or without fibrosis.

          2. Patients 75 years or younger

          3. Patients must have an HLA matched or at least a 9/10 antigen (A, B, C, DQ or DR)
             matched related or unrelated donor.

          4. Patients must have a Zubrod PS 2 or less.

          5. Creatinine &lt; 1.6 mg/dl

          6. Ejection fraction &gt;/= 40%, unless cleared by cardiology

          7. Serum direct bilirubin &lt; 2 mg/dl (unless due to Gilbert's syndrome), serum glutamate
             pyruvate transaminase (SGPT) &lt;/= 4 x normal values

          8. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), or
             diffusing capacity of lung for carbon monoxide (DLCO) &gt;/= 40% of expected.

          9. Negative Beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization.

        Exclusion Criteria:

          1. Uncontrolled life-threatening infections

          2. HIV positive

          3. Patients with Active viral hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday Popat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>November 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2018</results_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Myelofibrosis</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Antithymocyte Globulin</keyword>
  <keyword>ATG</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT00475020/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants With Myelofibrosis and Myelodysplastic Syndrome</title>
          <description>Allogeneic stem cell transplantation (SCT) with preparative regimen of fludarabine and busulfan in myelofibrosis and myelodysplastic syndrome</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance Denial</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Donor not able to donate the last minute</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants With Myelofibrosis and Myelodysplastic Syndrome</title>
          <description>Allogeneic stem cell transplantation (SCT) with preparative regimen of fludarabine and busulfan in myelofibrosis and myelodysplastic syndrome</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="27" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Non-relapse Mortality at 100 Days Post-transplant</title>
        <description>To evaluate the safety of Fludarabine/Busulfan as conditioned regimen for allogeneic stem cell transplantation in patients with myelofibrosis/myelodysplastic syndrome at 100 days post-transplant</description>
        <time_frame>Non-relapse mortality at 100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Myelofibrosis and Myelodysplastic Syndrome</title>
            <description>Allogeneic stem cell transplantation (SCT) with preparative regimen of fludarabine and busulfan in myelofibrosis and myelodysplastic syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Non-relapse Mortality at 100 Days Post-transplant</title>
          <description>To evaluate the safety of Fludarabine/Busulfan as conditioned regimen for allogeneic stem cell transplantation in patients with myelofibrosis/myelodysplastic syndrome at 100 days post-transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organ Failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sudden death: likely due to ischemic cardiac event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of This Therapy 3 Years Post-transplant</title>
        <description>Efficacy Assessed as Number of Participants with Overall Survival, Leukemia Progression, Primary Graft Failure and Complete Hematological Response. Primary graft failure is defined as failure to achieve an ANC &gt;/= 0.5 x 10 (9)/L for 3 consecutive days and evidence of donor chimerism by Day +28. Complete hematological response is defined by hemoglobin &gt;/= 120 g/L; or achievement of transfusion independence, with stable Hb &gt; 110 g/L, for RBC transfusion-dependent participants; Spleen not palpable; platelet count 150 x 10 (9)/L; White blood cell 4 x 10 (9)/L to 10 x 10(9)/L.</description>
        <time_frame>Up to 3 years post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Myelofibrosis and Myelodysplastic Syndrome</title>
            <description>Allogeneic stem cell transplantation (SCT) with preparative regimen of fludarabine and busulfan in myelofibrosis and myelodysplastic syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of This Therapy 3 Years Post-transplant</title>
          <description>Efficacy Assessed as Number of Participants with Overall Survival, Leukemia Progression, Primary Graft Failure and Complete Hematological Response. Primary graft failure is defined as failure to achieve an ANC &gt;/= 0.5 x 10 (9)/L for 3 consecutive days and evidence of donor chimerism by Day +28. Complete hematological response is defined by hemoglobin &gt;/= 120 g/L; or achievement of transfusion independence, with stable Hb &gt; 110 g/L, for RBC transfusion-dependent participants; Spleen not palpable; platelet count 150 x 10 (9)/L; White blood cell 4 x 10 (9)/L to 10 x 10(9)/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall survival at 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukemia progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary graft failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete hematological remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>January 2006 to May 2012</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Participants With Myelofibrosis and Myelodysplastic Syndrome</title>
          <description>Allogeneic stem cell transplantation (SCT) with preparative regimen of fludarabine and busulfan in myelofibrosis and myelodysplastic syndrome</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Liver GvHD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Secondary graft failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI GvHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Elevated transminitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin GvHD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Poor graft function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ABO incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI GvHD</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Upper GI GvHD</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver GvHD</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Veno-occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Elevated transminitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Infectious pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>BK virus associated hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ATG induced fevers</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Neutropenic fevers</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fevers</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hemorrhagic cystits</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ATG induced shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin GvHD</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ATG induced skin rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Popat,Uday,M.D. / Stem Cell Transplantation</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-3055</phone>
      <email>UPOPAT@MDANDERSON.ORG</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

